SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Inclusion Criteria: * Patients 18 or older * Unresectable or metastatic sporadic or NF1 associated high-grade MPNST * Experienced progression after one or more prior regimens of cytotoxic chemotherapy * Patients must be able to swallow tablets * Patients must have measurable disease, defined as at least one tumor that is measurable * Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a previously radiated field may be enrolled if it has been at least 4 weeks since the last dose of radiation therapy * Patients must have recovered from the toxic effects of all prior therapy before entering this study * Adequate organ function * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Patents who received an anthracycline prior to enrollment must have an ejection fraction ≥ 50% * Subjects of childbearing potential requires acceptable form of birth control * Informed consent Exclusion Criteria: * Patients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug or patients receiving prior treatment with investigational drugs 4 weeks of the start of study drug * Patients may not be currently receiving strong inhibitors of CYP3A4, and may not have received these medications within 1 week of entry * Prior radiotherapy within 4 weeks of the start of study drug * Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, * Patients who have not recovered from the side effects of any major surgery * Patients that may require major surgery during the course of the study * Less than 7 days have passed from core biopsies or other minor surgical procedures excluding placement of a vascular access device * Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent(Topical or inhaled corticosteroids are allowed) * Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases * Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * Female patients who are pregnant or breast feeding * Patients who have received prior treatment with an mTOR inhibitor or bevacizumab * Patients with known hypersensitivity to rapamycins * concurrent use of anti-coagulant drugs * Patients using Seville orange, star fruit, grapefruit and their juices, and St. John's Wort * Patients taking enzyme inducing anticonvulsants